Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: Cancer Res. 2010 May 11;70(11):4560–4568. doi: 10.1158/0008-5472.CAN-09-3596

Figure 1. Representative western blots showing JunD and Androgen Receptor (AR) in an immunocomplex in LNCaP cell lysates.

Figure 1

A. Immunoprecipitation (IP) of LNCaP whole cell lysate was performed using a rabbit polyclonal antibody against JunD (sc-74X) (IP:JunD). Immunoprecipitates were analyzed by western blot (WB) using monoclonal antibody against human AR (sc-7305) (WB:AR). Lane (1): IP with JunD antibody, Lane (2): IP with non-specific IgG, Lane (3): total LNCaP cell lysate.

B. IP of LNCaP whole cell lysate was performed using AR antibody (sc-7305) (IP:AR) and WB analysis using JunD antibody (sc-74X) (WB:JunD). Lane (1): IP with AR antibody, Lane (2): total LNCaP cell lysate, Lane (3): IP with non-specific IgG.

Positions of molecular size markers 148 kDa (A) and 50 kDa (B) are shown on the right. The experiment was repeated 3 times with similar results.

C. IP:JunD/WB:AR of LNCaP nuclear and cytoplasmic extracts was performed as described in (A) above. Lane (1): nuclei from cells treated with R1881 (+R), Lane (2): nuclei from untreated (−R) cells, Lane (3): cytoplasm from cells treated with R1881 and Lane (4): cytoplasm from untreated cells.

D. IP:AR/WB:JunD of LNCaP nuclear and cytoplasmic extracts was performed as described in (B) above. Lane (1): nuclei from cells treated with R1881 (+R), Lane (2): nuclei from untreated (−R) cells, Lane (3): cytoplasm from cells treated with R1881 and Lane (4): cytoplasm from untreated cells.